Dexamethasone implant with fixed or individualized regimen in the treatment of diabetic macular oedema: six-month outcomes of the UDBASA study

Acta Ophthalmologica

Volumn 95, Issue 4, 2017, Pages e255-e260

  Sarao, Valentina ^a,b   Veritti, Daniele ^a,b   Furino, Claudio ^c   Giancipoli, Ermete ^d   Alessio, Giovanni ^c   Boscia, Francesco ^d   Lanzetta, Paolo ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b Istituto Europeo di Microchirurgia Oculare   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

as needed; dexamethasone; diabetic macular oedema; Ozurdex; pro re nata

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; ITALY; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; SIDE EFFECT; VISUAL IMPAIRMENT; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; RETINA MACULA LUTEA; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85011023520     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13395     Document Type: Article

References (14)

1. Boyer DS, Yoon YH, Belfort R Jr et al. (2014): Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121: 1904–1914.
2. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD & Welty D (2011): Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52: 80–86.
3. Ding J & Wong TY (2012): Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 12: 346–354.
4. Dugel PU, Bandello F & Loewenstein A (2015): Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 9: 1321–1335.
5. Funatsu H, Noma H, Mimura T, Eguchi S & Hori S (2009): Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116: 73–79.
6. IDF Diabetes Atlas Sixth Edition (2013): version online of IDF Atlas. Available at: http://www.idf.org/diabetesatlas. ISBN:2-930229-85-3. (Accessed on 29 Dec 2016)
7. Keenan TD, Johnston RL, Donachie PH, Sparrow JM, Stratton IM & Scanlon P (2013): United Kingdom National Ophthalmology Database Study: diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye 27: 1397–1404.
8. Lee SS, Hughes P, Ross AD & Robinson MR (2010): Biodegradable implants for sustained drug release in the eye. Pharm Res 27: 2043–2053.
9. Lee WJ, Kang MH, Seong M & Cho HY (2012): Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 96: 1426–1430.
10. Maier R, Weger M, Haller-Schober EM et al. (2008): Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 14: 637–643.
11. Mathew C, Yunirakasiwi A & Sanjay S (2015): Updates in the management of diabetic macular edema. J Diabetes Res 2015: 794036.
12. Thakur A, Kadam R & Kompella UB (2011): Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol 129: 914–920.
13. Varma R, Bressler NM, Doan QV et al. (2014): Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132: 1334–1340.
14. Yau JW, Rogers SL, Kawasaki R et al. (2012): Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556–564.